Literature DB >> 8234268

Probing the role of loop 2 in Ras function with unnatural amino acids.

H H Chung1, D R Benson, V W Cornish, P G Schultz.   

Abstract

The YDPT sequence motif (residues 32-35) in loop 2 (residues 32-40) of Ha-Ras p21 protein is conserved in the Ras protein family. X-ray crystal structures have revealed significant conformational differences in this region between the GTP- and GDP-bound forms. Moreover, mutations in this region block neoplastic transformation and prevent interaction with GTPase-activating protein (GAP), suggesting that this region may contribute to the effector function of Ras. To better understand the structural features required for GAP interaction and GTPase activity, the expanded repertoire of unnatural amino acid mutagenesis has been used to investigate the roles of the key residues, Pro-34, Thr-35, and Ile-36. A Pro-34-->methanoproline mutant, in which residue 34 is locked in the trans conformation, was found to retain high levels of intrinsic and GAP-activated GTPase activity, making unlikely conformational isomerization at this position. Deletion of a single methyl group from Ile (Ile-36-->norvaline) abolished GAP activation of Ras, revealing a remarkable specificity in this protein-protein interaction. Finally, replacement of Thr-35 with diastereomeric allo-threonine led to inactivation of Ras, demonstrating the importance of the orientation of this critical residue in Ras function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234268      PMCID: PMC47730          DOI: 10.1073/pnas.90.21.10145

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Structure of ras proteins.

Authors:  L Tong; M V Milburn; A M de Vos; S H Kim
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

2.  A general method for site-specific incorporation of unnatural amino acids into proteins.

Authors:  C J Noren; S J Anthony-Cahill; M C Griffith; P G Schultz
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

3.  3'-Phosphatase activity in T4 polynucleotide kinase.

Authors:  V Cameron; O C Uhlenbeck
Journal:  Biochemistry       Date:  1977-11-15       Impact factor: 3.162

4.  Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins.

Authors:  M V Milburn; L Tong; A M deVos; A Brünger; Z Yamaizumi; S Nishimura; S H Kim
Journal:  Science       Date:  1990-02-23       Impact factor: 47.728

5.  In vitro suppression of an amber mutation by a chemically aminoacylated transfer RNA prepared by runoff transcription.

Authors:  C J Noren; S J Anthony-Cahill; D J Suich; K A Noren; M C Griffith; P G Schultz
Journal:  Nucleic Acids Res       Date:  1990-01-11       Impact factor: 16.971

Review 6.  Prenyl proteins in eukaryotic cells: a new type of membrane anchor.

Authors:  J A Glomset; M H Gelb; C C Farnsworth
Journal:  Trends Biochem Sci       Date:  1990-04       Impact factor: 13.807

Review 7.  ras GTPase activating protein: signal transmitter and signal terminator.

Authors:  F McCormick
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

8.  Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation.

Authors:  E F Pai; W Kabsch; U Krengel; K C Holmes; J John; A Wittinghofer
Journal:  Nature       Date:  1989-09-21       Impact factor: 49.962

9.  Molecular cloning of two types of GAP complementary DNA from human placenta.

Authors:  M Trahey; G Wong; R Halenbeck; B Rubinfeld; G A Martin; M Ladner; C M Long; W J Crosier; K Watt; K Koths
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

Review 10.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

View more
  7 in total

Review 1.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

2.  Inversion of the Side-Chain Stereochemistry of Indvidual Thr or Ile Residues in a Protein Molecule: Impact on the Folding, Stability, and Structure of the ShK Toxin.

Authors:  Bobo Dang; Rong Shen; Tomoya Kubota; Kalyaneswar Mandal; Francisco Bezanilla; Benoit Roux; Stephen B H Kent
Journal:  Angew Chem Int Ed Engl       Date:  2017-02-14       Impact factor: 15.336

3.  Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.

Authors:  Martin Zenker; Katarina Lehmann; Anna Leana Schulz; Helmut Barth; Dagmar Hansmann; Rainer Koenig; Rudolf Korinthenberg; Martina Kreiss-Nachtsheim; Peter Meinecke; Susanne Morlot; Stefan Mundlos; Anne S Quante; Salmo Raskin; Dirk Schnabel; Lars-Erik Wehner; Christian P Kratz; Denise Horn; Kerstin Kutsche
Journal:  J Med Genet       Date:  2006-10-20       Impact factor: 6.318

Review 4.  Regulating the regulator: post-translational modification of RAS.

Authors:  Ian M Ahearn; Kevin Haigis; Dafna Bar-Sagi; Mark R Philips
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

Review 5.  Why nature really chose phosphate.

Authors:  Shina C L Kamerlin; Pankaz K Sharma; Ram B Prasad; Arieh Warshel
Journal:  Q Rev Biophys       Date:  2013-01-15       Impact factor: 5.318

6.  Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.

Authors:  Harrison J Hocker; Kwang-Jin Cho; Chung-Ying K Chen; Nandini Rambahal; Sreenivasa Rao Sagineedu; Khozirah Shaari; Johnson Stanslas; John F Hancock; Alemayehu A Gorfe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-04       Impact factor: 11.205

7.  Aminoacyl-tRNA recognition by the FemXWv transferase for bacterial cell wall synthesis.

Authors:  Matthieu Fonvielle; Maryline Chemama; Régis Villet; Maxime Lecerf; Ahmed Bouhss; Jean-Marc Valéry; Mélanie Ethève-Quelquejeu; Michel Arthur
Journal:  Nucleic Acids Res       Date:  2009-01-16       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.